Lumosa Therapeutics Co., Ltd. (TPEX:6535)

Lumosa Therapeutics Ratios and Metrics

Market cap in millions TWD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Apr 1, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	29,219	42,224	11,268	6,425	6,117	5,194
Market Cap Growth	274.74%	274.74%	75.37%	5.04%	17.77%	28.50%
Enterprise Value	27,891	41,699	10,380	5,254	4,757	4,625
Last Close Price	173.00	250.00	68.15	39.31	40.16	35.03
PE Ratio	-	-	-	-	63.75	-
PS Ratio	1078.41	1078.41	197.97	241.17	352.32	239.89
PB Ratio	15.28	21.91	7.89	3.85	2.89	3.28
P/TBV Ratio	22.09	22.09	8.05	4.01	2.95	3.68
EV/Sales Ratio	1065.00	1065.00	182.37	197.19	273.96	213.59
Debt / Equity Ratio	0.00	0.00	0.01	0.00	0.01	0.01
Asset Turnover	0.02	0.02	0.03	0.01	0.01	0.01
Inventory Turnover	0.21	0.21	0.14	0.13	0.13	0.31
Quick Ratio	6.92	6.92	3.98	5.65	6.60	6.83
Current Ratio	7.64	7.64	4.76	6.44	7.23	7.07
Return on Equity (ROE)	-26.03%	-26.03%	-16.16%	-26.63%	5.18%	-24.54%
Return on Assets (ROA)	-11.78%	-11.78%	-13.26%	-9.03%	-13.01%	-13.73%
Return on Capital (ROIC)	-13.22%	-13.22%	-15.07%	-10.05%	-14.42%	-16.07%
Earnings Yield	-1.45%	-1.01%	-2.11%	-7.70%	1.57%	-6.21%
FCF Yield	-1.02%	-0.70%	-3.04%	-4.71%	-7.40%	-2.50%
Buyback Yield / Dilution	-0.64%	-0.64%	-0.03%	-7.61%	-24.92%	-3.01%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.